Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (2657)	1/23/2001 4:37:12 PM
From: Biomaven	Respond to of 52153

Thanks, Wilder. losing the royalty from CABG patients getting valve replacements Here again the issue was that the increased level of surgery drove up the CK-MB level in all patients, drug or placebo. So the effect of the drug (if any) is effectively hidden in the increased "noise" of the surgery. However, it does not mean those patients won't still benefit from the drug on some other measure, like cognitive or long-term morbidity/mortality. It might possibly be that troponin levels (!) would tease out the positive effects of the drug better. <g> Peter

To: keokalani'nui who wrote (2657)	1/24/2001 11:56:23 PM
From: Ian@SI	Respond to of 52153

ALXN: Wilder, Following are today's DJNewswire headlines on ALXN. They do give a somewhat different impression than Peter's. Ian. ++++++++++ ALEXION PHARMACEUTICALS INC Alexion Is Expected to Announce Heart Drug Had Successful Trial Alexion Pharma Pres/CEO: Drug Results Unexpectedly Strong Small-Cap Issues Gain Ground As Investors Focus on Earnings Alexion: C5 Inhibitor Monoclonal Cuts Endpoint Of Death Alexion Pharma Up 19% After Phase IIb Drug Results